Coronavirus Clinical Trial
— HYCOVIDOfficial title:
Hydroxychloroquine Versus Placebo in Patients Presenting COVID-19 Infection and at Risk of Secondary Complication: a Prospective, Multicentre, Randomised, Double-blind Study
Verified date | April 2020 |
Source | University Hospital, Angers |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
A new human coronavirus responsible for pneumonia, SARS-CoV-2, emerged in China in December
2019 and has spread rapidly. COVID-19, the disease caused by this virus, has a very
polymorphous clinical presentation, which ranges from upper respiratory tract infections to
acute respiratory distress syndrome. It may appear serious straightaway or may evolve in two
stages, with a worsening 7 to 10 days after the first clinical signs, potentially linked to a
cytokine storm and accompanied by a high risk of thrombosis. The global mortality rate of
COVID-19 is between 3% and 4%, with severe forms being more frequent among older patients.
Management is symptomatic as no antiviral treatment has demonstrated any clinical benefit in
this condition. Hydroxychloroquine is a derivative of chloroquine commonly used in some
autoimmune diseases, such as systemic lupus erythematosus. It is active in vitro in cellular
models of infection by many viruses such as HIV, hepatitis C or SARS-CoV. However, its
interest in viral infections in humans has not been demonstrated.
Very recently, a preliminary uncontrolled study evaluated the effect of hydroxychloroquine on
viral shedding in subjects with COVID-19. Among 20 patients treated with hydroxychloroquine
at a dose of 600 mg per day, the percentage of patients with detectable SARS-CoV-2 RNA in the
nasopharynx decreased from 100% at inclusion (start of treatment) to 43% six days later. In
comparison, 15 of 16 untreated patients had a positive RT-PCR six days after inclusion.
Furthermore, hydroxychloroquine has immunomodulating and anti-inflammatory properties, which
could theoretically prevent or limit secondary worsening.
The research hypothesis is that treatment with hydroxychloroquine improves prognosis and
reduces the risk of death or use for invasive ventilation in patients with COVID-19.
Status | Terminated |
Enrollment | 259 |
Est. completion date | June 18, 2020 |
Est. primary completion date | June 18, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Age = 18 years old - Symptomatic infection with COVID-19 confirmed by positive RT-PCR SARS-CoV-2 or, failing that, by thorax CT-scan suggesting viral pneumopathy of peripheral predominance in a clinically significant context. - Diagnosis in the previous two calendar days or, for an asymptomatic patient at the time of virological diagnosis, onset of symptoms in the previous two calendar days. - Patient having at least one of the following risk factors for developing complications: - Age =75 years old - Age between 60 and 74 years old and presence of at least one comorbidity among the following: obesity (body mass index = 30 kg/m²), arterial hypertension requiring treatment, diabetes mellitus requiring treatment - Need for supplemental oxygen to reach a peripheral capillary oxygen saturation of more than 94% (SpO2 > 94%), or a ratio of partial oxygen pressure to the fraction of inspired oxygen less than or equal to 300 mmHg (PaO2/FiO2 = 300 mmHg). - Patient affiliated to a social security scheme. - Written and signed consent of the patient or a relative or emergency inclusion procedure. Exclusion criteria - Last RT-PCR negative for SARS-CoV-2 - Peripheral capillary oxygen saturation less than or equal to 94% (SpO2 = 94%) despite oxygen therapy greater than or equal to 3 L/min (> 3 L/min) - Organ failure requiring admission to a critical or intensive care unit. - Comorbidity that is life threatening in the short-term (life expectancy < 3 months) - Any reason that makes patient follow-up throughout the study impossible - Current treatment with hydroxychloroquine - Absolute contraindication to treatment with hydroxychloroquine (known hypersensitivity, retinopathy, concomitant treatment with risk of ventricular disorders, particularly torsades de pointe, known deficit of glucose-6-phosphate dehydrogenase, porphyria) - Hypokalaemia < 3.5 mmol/L - Corrected QT prolongation (QTc = 440 ms in men and 460 ms in women). - Child-Pugh's class C liver cirrhosis - Chronic kidney failure with estimated GFR = 30 ml/min, or = 40 ml/min in patients with concomitant treatment with azithromycin - Women who are pregnant, breastfeeding, or parturient |
Country | Name | City | State |
---|---|---|---|
France | CH Agen | Agen | |
France | CHU Amiens | Amiens | |
France | CHU Angers | Angers | |
France | CH Auxerre | Auxerre | |
France | APHP Avicenne | Bobigny | |
France | CHU Brest | Brest | |
France | CHU Caen | Caen | |
France | CH Chalon Sur Saône | Chalon Sur Saône | |
France | CH Cherbroug | Cherbourg | |
France | CH Cholet | Cholet | |
France | CH Colmar | Colmar | |
France | CH Compiègne | Compiègne | |
France | APHP Henri Mondor | Créteil | |
France | CH Intercommunal Créteil | Créteil | |
France | CHU Dijon | Dijon | |
France | APHP Joffre Dupuytren | Draveil | |
France | CHD Vendée | La Roche-sur-Yon | |
France | CH Laval | Laval | |
France | CH Le Mans | Le Mans | |
France | CH Emile Roux | Le Puy-en-Velay | |
France | APHP Emile ROUX | Limeil-Brevannes | |
France | CHU Limoges | Limoges | |
France | CH Lorient | Lorient | |
France | Hôpital Européen - Marseille | Marseille | |
France | Hôpital Saint-Joseph | Marseille | |
France | CH Melun | Melun | |
France | CHU Nantes | Nantes | |
France | Hôpital Privé du Confluent | Nantes | |
France | CH Niort | Niort | |
France | CHR Orléans | Orléans | |
France | APHP Saint-Antoine | Paris | |
France | GH Croix Saint Simon | Paris | |
France | La Pitié-Salpétrière | Paris | |
France | CHU Poitiers | Poitiers | |
France | CH Pointoise | Pontoise | |
France | CH Quimper | Quimper | |
France | CH Saint-Brieuc | Saint-Brieuc | |
France | CHU Saint-Etienne | Saint-Étienne | |
France | CH Saint-Nazaire | Saint-Nazaire | |
France | CHU Toulouse | Toulouse | |
France | CH Tourcoing | Tourcoing | |
France | CHU Tours | Tours | |
France | CH Valenciennes | Valenciennes | |
France | Clinique Tessier Valenciennes | Valenciennes | |
France | CH Vannes | Vannes | |
France | CH Versailles | Versailles | |
Monaco | CH Princesse Grace | Monaco |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Angers |
France, Monaco,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of death from any cause, or the need for intubation and mechanical ventilation during the 14 days following inclusion and start of treatment. | Day 14 | ||
Secondary | Number of death from any cause, or the need for intubation and mechanical ventilation during the 28 days following inclusion and start of treatment. | Day 28 | ||
Secondary | Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 14 | WHO Ordinal Scale for Clinical Improvement ranges from 0 to 8, higher score meaning poorer outcome | Day 14 | |
Secondary | Clinical evolution on the WHO Ordinal Scale for Clinical Improvement for COVID-19 between day 0 and day 28. | WHO Ordinal Scale for Clinical Improvement ranges from 0 to 8, higher score meaning poorer outcome | Day 28 | |
Secondary | Number of all-cause mortality at day 14 | Day 14 | ||
Secondary | Number of all-cause mortality at day 28 | Day 28 | ||
Secondary | Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 5 | Day 5 | ||
Secondary | Rate of positive SARS-CoV-2 RT-PCR on nasopharyngeal samples at day 10 | Day 10 | ||
Secondary | The rate of venous thromboembolic events at day 28, documented and confirmed by an adjudication committee. | Day 28 | ||
Secondary | Number of all-cause mortality at day 28 in patients aged 75 and older | day 28 | ||
Secondary | Clinical evolution on the WHO OSCI scale for COVID-19 between day 0 and day 28 for patients aged 75 or older | day 28 | ||
Secondary | Rate of severe adverse events at day 28 | day 28 | ||
Secondary | Number of all-cause mortality at day 14 in patients aged 75 and older | day 14 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05065827 -
Lung Ultrasound Findings in Patients With COVID-19 in a UK ED
|
||
Recruiting |
NCT05359770 -
Association of Inspiratory Muscle Training With HD-tDCS for Assistance to Patients With Long Covid-19
|
N/A | |
Completed |
NCT04515147 -
A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19
|
Phase 2 | |
Not yet recruiting |
NCT06025812 -
Clinical Study of Omicron BA.4/5-Delta Strain Recombinant Novel Coronavirus Protein Vaccine (CHO Cells)
|
N/A | |
Recruiting |
NCT05289115 -
Protocol for Assistance to Patients With Long Covid-19 Undergoing Treatment With HD-tDCS
|
N/A | |
Completed |
NCT04953078 -
A Study to Evaluate Safety, Tolerability, and Reactogenicity of an RBD-Fc-based Vaccine to Prevent COVID-19
|
Phase 1 | |
Completed |
NCT04779138 -
Increasing Vaccine Uptake in Underresourced Public Housing Areas
|
N/A | |
Not yet recruiting |
NCT05868239 -
Impact of Aerosol Box Use During Cardiopulmonary Arrest: A Multicenter Study
|
N/A | |
Completed |
NCT04818164 -
Prone Position Improves End-Expiratory Lung Volumes in COVID-19 Acute Respiratory Distress Syndrome
|
||
Completed |
NCT04690413 -
NOWDx Test for the Detection of Antibodies to COVID-19
|
N/A | |
Terminated |
NCT04530448 -
Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization
|
Phase 4 | |
Completed |
NCT04572399 -
UVA Light Device to Treat COVID-19
|
N/A | |
Recruiting |
NCT04610567 -
Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04772170 -
Observational Digital Biomarker Discovery in Respiratory Virus Challenge Studies
|
||
Recruiting |
NCT04581954 -
Inflammatory Signal Inhibitors for COVID-19 (MATIS)
|
Phase 1/Phase 2 | |
Completed |
NCT04405934 -
COG-UK Project Hospital-Onset COVID-19 Infections Study
|
N/A | |
Enrolling by invitation |
NCT04484025 -
SPI-1005 Treatment in Moderate COVID-19 Patients
|
Phase 2 | |
Completed |
NCT05572840 -
Wear Your Mask, Wash Your Hands, Don't Get COVID-19
|
N/A | |
Withdrawn |
NCT04838847 -
A Study to Evaluate the Immunogenicity and Safety of the SARS-CoV-2 mRNA Vaccine CVnCoV in Elderly Adults Compared to Younger Adults for COVID-19
|
Phase 3 | |
Terminated |
NCT04371978 -
Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19
|
Phase 3 |